NCT05802511

Study of Exablate Model 4000 Type 1.0/1.1 Following the Treatment of Neuropathic Pain

Post Market Study of Exablate Model 4000 Type 1.0/1.1 Following the Treatment of Neuropathic Pain

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: IRCCS Centro Neurolesi Bonino Pulejo · Academic / Other
• Sex: All
• Age: 30 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

The Exablate 4000 obtained CE Mark for the treatment of Neuropathic Pain in December 2012. The purpose of this post market study is to obtain real world data on the safety and performance of the Exablate treatment for neuropathic pain. The objective of this study is to capture the change in pain intensity, physical/emotional function, and pain impact for patients diagnosed with neuropathic pain who undergo an Exablate treatment.

Detailed description

The purpose of this post market study is to obtain real world data on the safety and performance of the Exablate treatment for neuropathic pain.

Conditions

• Peripheral Neuropathy
• Neuropathic Pain

Interventions

Type	Name	Description
DEVICE	Exablate treatment	Exablate treatment for Neuropathic Pain

Timeline

• Start date: 2020-02-01
• Primary completion: 2021-02-15
• Completion: 2021-02-28
• First posted: 2023-04-06
• Last updated: 2023-04-06

Locations

1 site across 1 country: Italy